Global Dry Eyes Disease Market Trend, Analysis, Growth Report, 2026-2034
REPORT DETAILS
Dry Eye Disease Market Size and Growth Outlook
The global dry eyes disease market size was valued at USD 7.97 billion in 2025. The market is projected to grow at a CAGR of 9.35% from 2026 to 2034. Key factors driving demand for dry eye disease include an aging global population, increasing use of digital screens, and environmental factors like low humidity and pollution.
Market Statistics
Dry Eye Disease Market Key Takeaways
- North America led the global Dry Eye Disease market with a 41.5% revenue share in 2025. This dominance is attributed to the increasing corporate workforce, prolonged screen exposure, a growing aging population, and widespread access to advanced ophthalmic care.
- Asia Pacific is expected to register the highest CAGR of 8.9% during the forecast period. Rising digital screen usage, increasing air pollution, expanding healthcare infrastructure, and greater awareness of eye health are expected to drive regional market growth.
- The Topical Corticosteroids segment held the largest market share of 30.6% in 2025. Their rapid anti-inflammatory effects, high clinical efficacy, and widespread use for managing acute dry eye symptoms contribute to the segment's dominance.
- The E-commerce distribution channel is projected to grow at a CAGR of 9.8% during the forecast period. Growth is fueled by the convenience of online purchasing, expanding smartphone penetration, competitive pricing, and increasing consumer preference for home delivery of ophthalmic products.
- The Artificial Tears segment is projected to register a CAGR of 9.5% during the forecast period. Their ability to lubricate and protect the ocular surface, relieve irritation, and provide long-term symptom management continues to support strong demand across the global market.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Dry Eye Disease Definition, Causes and Symptoms
Dry eye disease (DED) is a common chronic condition. This eye disease occurs when the eyes do not produce enough tears or when the quality of tears is poor. This imbalance causes symptoms such as irritation, burning, redness, and blurred vision. Dry eye disease (DED) can result from aging, hormonal changes, prolonged screen time, environmental factors, certain medications, or underlying health conditions. This disease may damage the corneal surface and affect vision quality, which makes early diagnosis and management essential.
The growing aging population acorss the globe is leading to the market growth. According to a recent data, by 2050, the aging population is expected to grow to 1.5 billion. Aging population are more prone to conditions such as reduced blink rates, hormonal changes. This contribute to dry eye symptoms, requiring the need for effective medication. Moreover, aging population are also more prone to diabetes, arthritis, and glaucoma, which worsen eye dryness, further increasing the prevalence of the condition. According to statistics, about 425 to 430 million people worldwide have diabetes.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
Dry Eye Disease Market Drivers, Opportunities and Challenges
- The global dry eye disease market is fueled by increasing healthcare spending and a growing aging population.
- The growth in air pollution in South East Asia, particularly in India and Pakistan, is anticipated to increase demand for dry eye disease medication.
- The growing aging population, especially in developed countries, is creating a lucrative market opportunity.
- Lack of public awareness in various parts of the world may hamper the market growth.
AI Impact on Dry Eye Diagnosis, Treatment Planning and Teleophthalmology
- AI assists in improving the diagnosis of dry eye disease through image analysis of the eyes, tear film, and symptoms with more precision.
- AI helps in tailoring treatment to individuals through the identification of what causes dry eye disease.
- AI assists in conducting research through analysis of treatment results and patterns in the progression of disease.
- It enables the monitoring, treatment planning and delivery of teleophthalmology services to patients through predictive analytics and timely information.
How Does Dry Eye Disease Treatment Work?
Diagnosis - The doctor analyzes the eyes of the person and conducts many tests to determine what type of dry eye disease the person is having.
Cause Determination - The underlying cause behind the disease is determined, whether it is a lack of production of tears, evaporation of the tears, or meibomian gland malfunction.
Selection of Treatment - According to the determination, the doctor recommends a particular way of treating the condition, which includes artificial tears, prescription, or a medical device.
Symptom Relief - Through treatment, the patient gets relief as their eyes get lubricated and any sort of inflammation is removed.
Follow-Up – A follow-up visit may be required to monitor the effectiveness of the treatment process.
Long-Term Eye Care – Treatment and eye hygiene are important in managing the symptoms.
Dry Eye Disease Market Drivers and Restraints
Air Pollution and Digital Screen Exposure Driving Dry Eye Treatment Demand
The growth in air pollution in South East Asia, particularly in India and Pakistan, is anticipated to increase demand for dry eye disease medication. Pollutants such as particulate matter, smoke, dust, and toxic gases disrupt the tear film, and accelerate tear evaporation, leading to a higher prevalence of dry eye symptoms. Moreover, the growing urbanization these countries is also leading to high air pollution, which is increasing the prevalence of dry eye symptoms and creating the demand for dry eye disease medication. According to World Bank Group, India is urbanizing rapidly. By 2036, its towns and cities will be home to 600 million people, or 40 percent of the population, up from 31 percent in 2011. Moreover, increasing awareness-raising initiatives by public and private organizations is estimated to expand the dry eye syndrome treatment market.
IPL, Thermal Pulsation and Meibomian Gland Treatment Devices
Technological advancements have led to the improvement of treatment devices for dry eye disease for individuals with moderate to severe cases of the condition. Devices like thermal pulse technology, IPL, and tear stimulators address the root cause of the problem as opposed to just managing its symptoms. The devices work by promoting the functioning of meibomian glands, reducing inflammation, and restoring the stability of the tear film. The procedures are mostly carried out in eye care centers by specialists, and they provide permanent remedies for dry eyes problems. With the continuous improvement in technology within the eye care industry, the devices have become more effective and more accessible to patients.
Personalized Dry Eye Treatment for Tear-Film and Meibomian Gland Dysfunction
Personalized treatment has become an integral aspect of managing dry eye syndrome because the disorder may arise from various sources in each patient. Health practitioners evaluate the production of tears, tear composition, levels of inflammation, and functioning of meibomian glands prior to prescribing a treatment plan for a particular patient. Artificial tears, prescription drugs, medical devices, or a combination of the aforementioned methods may be prescribed depending on the diagnosis made. Personalized therapy enhances treatment efficacy and relieves symptoms effectively. Follow-up appointments make it easier for doctors to adjust treatment plans if needed.
Digital Eye Strain and Screen-Related Dry Eye Disease
The rise in the use of computers, smartphones, tablets, and other digital devices has led to an increase in dry eye syndrome around the world. People blink less frequently when looking at a screen, which leads to tears evaporating faster and results in dryness, irritation, and blurry vision. The excessive use of digital devices may also lead to eye strain and discomfort, particularly in students and office workers. As the usage of digital screens rises, awareness about the screen-related issues of the eyes is rising, and people are seeking treatment for them. Eye care specialists are also recommending healthy practices such as frequent pauses and maintaining correct screen distance. Increased screen usage is likely to be a crucial factor behind the growth of the dry eye treatment market.
Source: Polaris Market Research Analysis
Dry Eye Disease Market Segmentation by Disease Type, Drug, Technology and Channel
The market is primarily segmented based on drug type, technology, distribution channel, and region.
By Drug Type | By Technology | By Distribution Channel | By Region |
|
|
|
|
Source: Polaris Market Research Analysis
Dry Eye Disease Treatment Pipeline and Emerging Therapies
Some of the promising pipeline therapies for Dry Eye Disease (DED).
| New treatment | Developer/Company | Stage & Mechanism / Notes |
| Reproxalap | Aldeyra Therapeutics | Phase III—reduces ocular inflammation by blocking reactive aldehyde species (RASP). |
| PL9643 | Palatin Technologies | Phase III—a melanocortin-receptor agonist that helps control inflammation and repair the ocular surface. |
| SI-614 | Seikagaku Corporation | Phase III—stabilizes the tear film and supports corneal healing. |
| HU007 | Huons | Phase III—combines cyclosporine with trehalose to ease irritation and improve tear stability. |
| TRPM8-agonist drops (e.g., AR-15512) | Alcon / others | Late-stage—stimulates natural tear production by activating cold-sensing receptors. |
| BTV100 | BioTheraVision | Phase II—small-molecule eye drop being tested for safety and symptom relief. |
Source: Polaris Market Research Analysis
Dry Eye Disease Market by Drug Type: Artificial Tears, Corticosteroids, Cyclosporine and Tear Stimulants
The topical corticosteroids segment held the largest revenue share in 2025. This is attributed to its high efficacy and widespread adoption for acute cases. The ability of topical corticosteroids to reduce inflammation and itching encouraged healthcare providers and the normal population to adopt topical corticosteroids for the treatment of dry eye disease. Studies have also shown high rates of success of topical corticosteroids in the treatment of dry eye disease, which contributed to the segment's dominance.
The market share of artificial tears for dry eyes is projected to grow at a rapid pace in the coming years, owing to their ability to protect the surface of the eyes. Artificial tears provide immediate and temporary relief for dry eyes symoptoms. This is propelling the growth of the segment. The availability of artificial tears over-the-counter is also also leading to an increase in segment revenue.
Artificial Tears vs. Prescription Dry Eye Treatments
| Factor | Artificial Tears | Prescription Dry Eye Treatments |
| Purpose | To lubricate and hydrate the eyes | To treat the underlying condition of dry eyes |
| Ideal For | Symptoms of mild to moderate dry eyes | Symptoms of moderate to severe or chronic dry eyes |
| Effectiveness | To replace lost moisture and decrease pain | To lower inflammation or increase tear secretion |
| Accessibility | Readily available over the counter as a part of the growing artificial tears market | Given out under prescription by eye care professionals |
| Duration | Often used when required for immediate relief | Used as part of ongoing dry eye disease treatment |
Source: Polaris Market Research Analysis
Dry Eye Disease Market by Distribution Channel: Hospital, Retail, Specialty and E-Commerce
Based on distribution channels, e-commerce segment is estimated to hold a significant revenue share in 2034. This is attributed to its ability to provide convenience and the growing adoption of smartphones. Patients are now being inclined toward e-commerce distribution channels for comfort, availability, and prices. The growing usage of smartphones across the world is driving the world toward e-commerce platforms that are selling over-the-counter drugs for dry eye syndromes. The growing internet penetration worldwide is further fueling the segment growth.
Source: Polaris Market Research Analysis
Use Cases of Dry Eye Disease Treatments
| Use Case | Benefits of Treatment |
| Chronic Dry Eye Condition | Provides relief from chronic dryness, irritation, and discomfort as well as helps in maintaining the stability of tears. |
| Digital Eye Strain | Aids in reducing dryness and fatigue to the eyes because of excessive use of computers and phones. |
| LASIK Post-Recovery | Brings back the moisture in eyes post-LASIK surgery or other forms of vision correction surgeries. |
| Dry Eyes for Contact Lens Users | Makes the eyes more comfortable by reducing irritation. |
| Dry Eye Due to Inflammation | With prescription treatment, the inflammation is reduced, thus increasing tear production. |
| Elderly Eye Care | Aids in managing age-related dryness in tears. |
Source: Polaris Market Research Analysis
Dry Eye Disease Market Regional Analysis
North America held the largest market share in 2025. This is attributed to the increasing corporate culture and the growing aging population. According to the Government of Canada Statistics Report 2019, Canada's elderly population has reached 6,592,611, accounting for 17.5% of Canada's population. The increasing use of computers or digital screens, driven by rising corporate culture, also contributed to the regional dominance, as the high use of computers or digital screens causes DED symptoms. Moreover, the high healthcare spending and established healthcare infrastructure in the region, especially in the U.S., fueled the market dominance in 2025.
Asia Pacific is expected to grow at the fastest CAGR during the forecast period due to the increasing use of digital screens and growing pollution in many parts of the region. Pollutants such as particulate matter, smoke, and dust disrupt the tear film and accelerate tear evaporation, leading to a higher prevalence of dry eye symptoms. The growing medical tourism in many parts of the region, such as India, is also leading to the market growth in the region. For instance, the total number of Foreign Tourist Arrivals (FTAs) for medical purposes in India during 2025 (up to April) is 131,856, which constitutes approximately 4.1% of the total FTAs during this period. Moreover, the growth in urbanization in the region is further propelling the market growth. The urban population in Asia is expected to grow by 50% by 2050, according to the United Nations Human Settlements Programme.
Source: Polaris Market Research Analysis
Dry Eye Disease Market Competitive Landscape and Treatment Pipeline
There is strong competition in the dry eye disease market as pharmaceutical and medical device companies develop new treatments in an effort to better the services offered to patients. There have been several advancements in R&D, and manufacturers can now provide prescription and artificial tears, as well as devices designed to treat different types of dry eye disease. Many firms are increasing the scope of their products through alliances, acquisitions, and launches of products. Personalized dry eye therapy market options and better drug delivery systems are key focus areas for players in this industry.
Key Market Players
Some of the major players operating in the global dry eye disease market:
- Novartis AG
- AbbVie, Inc.
- Sun Pharmaceutical Industries Ltd.
- Santen Pharmaceutical Co., Ltd.
- AFT Pharmaceuticals
- Johnson & Johnson Services, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- OASIS Medical
- Oyster Point Pharma, Inc. (acquired by Viatris Inc.)
- Bausch Health Companies, Inc.
Dry Eye Disease Market Future Outlook
The dry eyes disease market is anticipated to experience steady growth in the coming years due to the growing incidence of this condition. Increasing usage of digital screens, an aging population, and higher awareness about eye health have been contributing to the growth in the market. Innovations in drugs, artificial tears, and device technology are offering patients more treatment alternatives. Improvements in the diagnostic tools available and personalized treatment methods have also been positively impacting patient management. With continued improvement in access to eye care services, the demand for dry eye treatments is set to increase further.
Dry Eye Disease Market Recent Developments and Product Approvals
- March 2026: Aldeyra Therapeutics, Inc. announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). The CRL is for the company’s reproxalap New Drug Application for dry eye disease. The agency cited inconsistencies in study results and a lack of substantial evidence of efficacy from completed trials.(source: aldeyra.com)
- February 2026: Nordic Pharma introduced Lacrifill, a novel therapy for dry eye disease, across the European Union.
- December 2025: The U.S. Food and Drug Administration (FDA) postponed the reproxalap PDUFA decision date to March 16, 2026, extending the review period for Aldeyra Therapeutics.
Dry Eye Disease Market Report Scope
| Report Attributes | Details |
| Market size value in 2025 | USD 7.97 billion |
| Market size value in 2026 | USD 8.69 billion |
| Revenue forecast in 2034 | USD 17.82 billion |
| CAGR | 9.35% from 2026 - 2034 |
| Base year | 2025 |
| Historical data | 2021 - 2024 |
| Forecast period | 2026 - 2034 |
| Quantitative units | Revenue in USD Billion and CAGR from 2026 to 2034 |
| Segments covered |
|
| Regional scope |
|
| Key companies | Abbott, AbbVie Inc., AFT Pharmaceuticals, Akorn Operating, Company LLC, Allergan, Allostera Pharma Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, I-Med Pharma Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Merck KGaA, Novaliq GmbH, Novartis AG, Otsuka America, Pharmaceutical, Inc., Pfizer Inc., Sanofi, Santen Pharmaceuticals Co. Ltd., Teva Pharmaceutical Industries Ltd |
Source: Polaris Market Research Analysis
Dry Eye Disease Market FAQs
• The global market size was valued at USD 7.97 billion in 2025 and is projected to grow to USD 17.82 billion by 2034.
• The global market is projected to register a CAGR of 9.35% during the forecast period.
• North America dominated the market in 2025.
• A few of the key players in the market include Abbott, AbbVie Inc., AFT Pharmaceuticals, Akorn Operating, Company LLC, Allergan, Allostera Pharma Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, I-Med Pharma Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Merck KGaA, Novaliq GmbH, Novartis AG, Otsuka America, Pharmaceutical, Inc., Pfizer Inc., Sanofi, Santen Pharmaceuticals Co. Ltd., Teva Pharmaceutical Industries Ltd.
• The topical corticosteroids segment dominated the market revenue share in 2025.
• Dry eye disease is associated with insufficient tear production in the eyes or premature tear evaporation. In addition, it may result from the aging process, long working time in front of screens, certain drugs, contact lenses, or any other medical conditions influencing tear production.
• Artificial tears help moisturize the eyes and reduce the symptoms of dryness and irritation, such as burning. Artificial tears are mostly prescribed for patients with mild or moderate dry eye symptoms; they can be purchased without a prescription.
• The main factor influencing the development of the dry eye disease market is the prevalence of dry eye syndrome due to increased screen time, an older population, and closer attention to eye health issues.
Download Sample Report of Dry Eyes Disease Market
Please fill out the form to request a customized copy of the research report.
